Skip to content

Glaukos GKOS Inventories

Inventories at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$14.58B+15.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$3.1B-2.8%
AbbVie logo
AbbVieABBV
$5.05B+11.6%
Boston Scientific logo
Boston ScientificBSX
$3.12B+8.7%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$896.4M+1.8%
Exelixis logo
ExelixisEXEL
$63.91M-11.2%

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's inventories?
Glaukos (GKOS) reported inventories of $62.38M in Q1 2026.
How has Glaukos's inventories changed year-over-year?
Glaukos's inventories increased by 4.9% year-over-year, from $59.46M to $62.38M.
What is the long-term trend for Glaukos's inventories?
Over 5 years (2020 to 2025), Glaukos's inventories has grown at a 32.1% compound annual growth rate (CAGR), from $15.81M to $63.56M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.